Celldex Therapeutics (CLDX) Change in Accured Expenses (2010 - 2026)

Celldex Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 84.42% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 50.67% increase from a year earlier, with the FY2025 full-year figure at -$753000.0, down 106.47% from the prior year.
• Change in Accured Expenses climbed to -$1.4 million in Q1 2026 per CLDX's latest filing, from -$7.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $13.1 million in Q3 2025 and bottomed at -$8.7 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is -$387000.0 (2022), against an average of $1.3 million.
• Across the five-year window, Change in Accured Expenses surged 6041.73% in 2023 and tumbled 493.46% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$139000.0 in 2022, then jumped by 6041.73% to $8.3 million in 2023, then decreased by 3.21% to $8.0 million in 2024, then plunged by 189.85% to -$7.2 million in 2025, then surged by 81.09% to -$1.4 million in 2026.
• Per Business Quant, the three latest CLDX Change in Accured Expenses figures stand at -$1.4 million (Q1 2026), -$7.2 million (Q4 2025), and $13.1 million (Q3 2025).